Personal genomic testing (the analysis of the DNA of individuals) is now available for less than $400. The consequences of personal genetic testing are often debated, with advocates arguing that genetic data can lead to improved health care and critics warning that consumers may be unduly worried upon learning results.
California regulations impose conditions on firms providing personal genomic testing. This symposium examines genomic testing technology, its ramifications, government regulation of the industry, and whether individuals should have their genome analyzed.
Linda Avey is co-founder and CEO of Curious, Inc., a personal data discovery platform. Previously, she co-founded 23andMe, the leading personal genetics company.
Daniel Ballon is Senior Policy Fellow in Technology Studies at the Pacific Research Institute. Dr. Ballon's research focuses on policies which promote innovation in the technology sector. He previously spent ten years conducting applied research in biotechnology, and his work has been published in leading biomedical journals.
Prior to joining PRI, he served as science and technology policy advisor for former Speaker of the House Newt Gingrich at the American Enterprise Institute.
Dr. Ballon received his Ph.D. in Molecular and Cell Biology from the University of California at Berkeley and a B.A. in Molecular Biology and Biochemistry from Wesleyan University.
Mark B. Gerstein
Mark B. Gerstein is an American physical and biological scientist working in bioinformatics.
As of 2006 he is co-director of the Yale Computational Biology and Bioinformatics program, and Albert L. Williams Associate Professor of Biomedical Informatics, Associate Professor of Molecular Biophysics & Biochemistry and Associate Professor of Computer Science at Yale University.
David C. Magnus
David C. Magnus, Ph.D. is Associate Professor of Pediatrics and Medicine, Stanford University. Magnus is also Director of the Stanford Center for Biomedical Ethics.